Clinical Trials Logo
  1. Home
  2. Preclinical Alzheimer's Disease
  3. NCT02045056

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

Preclinical Alzheimer's Disease Clinical Trial

Official title:
Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of gemfibrozil in modulating microRNA-107 levels for the prevention of Alzheimer's disease in subjects with intact cognition and mild cognitive impairment

Clinical Trial Description

Double-blind, placebo controlled, parallel-design. 48 cognitively-intact subjects, and 24 subjects with early cognitive decline (CDR 0.5) will be randomly assigned to treatment with gemfibrozil (600 mg orally twice a day) or placebo for 52 weeks. Safety assessments will include routine assessment of adverse events, safety labs, and brain magnetic resonance imaging. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02045056
Study type Interventional
Source University of Kentucky
Contact
Status Completed
Phase Early Phase 1
Start date May 2014
Completion date June 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06033066 - Financial Incentives and Recruitment to the APT Webstudy N/A
Enrolling by invitation NCT06416072 - Alzheimer's Plasma Extension
Recruiting NCT04851496 - Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
Terminated NCT04846426 - Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
Completed NCT04828122 - Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
Completed NCT03370744 - Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
Completed NCT02963415 - Concurrent Aerobic Exercise and Virtual Reality Cognitive Training N/A
Active, not recruiting NCT04004767 - TRC-PAD Program: In-Clinic Trial-Ready Cohort
Recruiting NCT04468659 - AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid Phase 3
Recruiting NCT04937959 - Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
Completed NCT04928976 - Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping
Terminated NCT04951284 - Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension